Myeloproliferative Neoplasms section

Myeloproliferative Neoplasms News & Features

Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms

Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms

A survey-based study investigated the relationship between symptom burden and incidence of medical disability leave among patients with MPNs.

Prevalence, Severity of Psychological Distress Higher in Patients Coping With Philadelphia-negative Myeloproliferative Neoplasm

Prevalence, Severity of Psychological Distress Higher in Patients Coping With Philadelphia-negative Myeloproliferative Neoplasm

Researchers sought to determine the prevalence and severity of anxiety and/or depression among patients with Philadelphia-negative MPNs.

Risk of Therapy-Related MDS, AML Increased by Use of Leukemogenic Chemotherapy Agents

Risk of Therapy-Related MDS, AML Increased by Use of Leukemogenic Chemotherapy Agents

Researchers sought to determine the association between chemotherapy, particularly platinum-based agents, and increased risk of tMDS/AML.

No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis

No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis

A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.

Recommended Therapies for Polycythemia Vera Underused

Recommended Therapies for Polycythemia Vera Underused

Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients.

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.

Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype

Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype

In a review of data from DANHES study, researchers determined the hazard ratio for developing myeloproliferative neoplasm — any or by subtype — among smokers, occasional smokers, and ex-smokers, compared with never smokers.

Case Study: Myelofibrosis Diagnosis and Early Intervention

Case Study: Myelofibrosis Diagnosis and Early Intervention

In this Case Study, Ms Lyle discusses diagnosis and early management of myelofibrosis in a 72-year-old male patient.

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs